CCNE1 and ovarian carcinoma: The investigators observed that cyclin E1 (CCNE1) was overexpressed in 30% of established ovarian cancer cell lines, and such cancer cells were 40 times more sensitive to SNS-032 therapy, a CDK2 small molecule inhibitor [46].